Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price hoisted by stock analysts at Leerink Swann from $132.00 to $135.00 in a research report issued to clients and investors on Thursday. The brokerage currently has a “market perform” rating on the biopharmaceutical company’s stock. Leerink Swann’s price objective would indicate a potential upside of 0.45% from the company’s current price.
A number of other research analysts have also recently weighed in on the stock. B. Riley reissued a “buy” rating and set a $205.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, January 19th. Chardan Capital reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Friday, January 19th. Piper Jaffray Companies reissued a “buy” rating and set a $182.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Sunday, January 7th. Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a research note on Friday, December 15th. Finally, BidaskClub cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. Alnylam Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $123.93.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up $0.10 on Thursday, hitting $134.39. 526,871 shares of the stock were exchanged, compared to its average volume of 975,784. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. Alnylam Pharmaceuticals has a fifty-two week low of $35.98 and a fifty-two week high of $147.63. The stock has a market cap of $13,220.00, a PE ratio of -25.60 and a beta of 2.98.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The business had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $28.15 million. During the same period last year, the business earned ($1.21) earnings per share. The company’s revenue for the quarter was up 24.8% on a year-over-year basis. equities analysts expect that Alnylam Pharmaceuticals will post -5.29 earnings per share for the current year.
In related news, EVP Akshay Vaishnaw sold 33,666 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the sale, the executive vice president now owns 45,201 shares in the company, valued at $5,490,113.46. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Michael Mason sold 36,745 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the sale, the vice president now owns 6,352 shares in the company, valued at approximately $835,859.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 274,075 shares of company stock worth $35,356,089. 4.30% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Strs Ohio acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $141,000. CENTRAL TRUST Co boosted its holdings in shares of Alnylam Pharmaceuticals by 746.3% in the 4th quarter. CENTRAL TRUST Co now owns 1,134 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 1,000 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $165,000. Fayerweather Charles acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $230,000. Finally, Watch Point Trust Co acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $235,000. Institutional investors own 88.41% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/27/alnylam-pharmaceuticals-alny-given-new-135-00-price-target-at-leerink-swann.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).